Your browser doesn't support javascript.
Dynamics of SARS-CoV-2 Variants of Concern in Vaccination Model City in the State of Sao Paulo, Brazil.
Slavov, Svetoslav Nanev; de La-Roque, Debora Glenda Lima; da Costa, Pericles Natan Mendes; Rodrigues, Evandra Strazza; Santos, Elaine Vieira; Borges, Josiane Serrano; Evaristo, Mariane; de Matos Maçonetto, Juliana; Marques, Adriana Aparecida; Milhomens, Jonathan; Rós, Felipe Augusto; Fonseca, Vagner; Lima, Alex Ranieri Jerônimo; Ribeiro, Gabriela; Lima, Loyze Paola Oliveira de; Garibaldi, Pedro Manuel Marques; Ferreira, Natasha Nicos; Moraes, Glenda Renata; Marqueze, Elaine Cristina; Barros, Claudia Renata Dos Santos; Martins, Antonio Jorge; Coutinho, Luiz Lehmann; Calado, Rodrigo Tocantins; Borges, Marcos; Elias, Maria Carolina; Sampaio, Sandra Coccuzzo; Giovanetti, Marta; Alcantara, Luiz Carlos Junior; Covas, Dimas Tadeu; Kashima, Simone.
  • Slavov SN; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • de La-Roque DGL; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • da Costa PNM; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Rodrigues ES; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Santos EV; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Borges JS; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Evaristo M; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • de Matos Maçonetto J; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Marques AA; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Milhomens J; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Rós FA; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Fonseca V; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Lima ARJ; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Ribeiro G; Pan-American Health Organization/World Health Organization, Lote 19-Avenida das Nações, SEN-Asa Norte, Brasília 70312-970, Brazil.
  • Lima LPO; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Garibaldi PMM; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Ferreira NN; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Moraes GR; Serrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil.
  • Marqueze EC; Serrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil.
  • Barros CRDS; Health Department, Tancredo Almeida Neves Street, 176, Serrana 14150-000, Brazil.
  • Martins AJ; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Coutinho LL; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Calado RT; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Borges M; College of Agriculture "Luiz de Queiroz", University of São Paulo, Pádua Dias Street, 235, Piracicaba 13418-900, Brazil.
  • Elias MC; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
  • Sampaio SC; Serrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil.
  • Giovanetti M; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Alcantara LCJ; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
  • Covas DT; Oswaldo Cruz Foundation, Rio de Janeiro 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil.
  • Kashima S; Department of Science and Technology for Humans and the Environment, University of Campus Bio-Medico di Roma, 00128 Rome, Italy.
Viruses ; 14(10)2022 09 29.
Article in English | MEDLINE | ID: covidwho-2066546
ABSTRACT
From a country with one of the highest SARS-CoV-2 morbidity and mortality rates, Brazil has implemented one of the most successful vaccination programs. Brazil's first model city vaccination program was performed by the CoronaVac vaccine (Sinovac Biotech) in the town of Serrana, São Paulo State. To evaluate the vaccination effect on the SARS-CoV-2 molecular dynamics and clinical outcomes, we performed SARS-CoV-2 molecular surveillance on 4375 complete genomes obtained between June 2020 and April 2022 in this location. This study included the period between the initial SARS-CoV-2 introduction and during the vaccination process. We observed that the SARS-CoV-2 substitution dynamics in Serrana followed the viral molecular epidemiology in Brazil, including the initial identification of the ancestral lineages (B.1.1.28 and B.1.1.33) and epidemic waves of variants of concern (VOC) including the Gamma, Delta, and, more recently, Omicron. Most probably, as a result of the immunization campaign, the mortality during the Gamma and Delta VOC was significantly reduced compared to the rest of Brazil, which was also related to lower morbidity. Our phylogenetic analysis revealed the evolutionary history of the SARS-CoV-2 in this location and showed that multiple introduction events have occurred over time. The evaluation of the COVID-19 clinical outcome revealed that most cases were mild (88.9%, 98.1%, 99.1% to Gamma, Delta, and Omicron, respectively) regardless of the infecting VOC. In conclusion, we observed that vaccination was responsible for reducing the death toll rate and related COVID-19 morbidity, especially during the gamma and Delta VOC; however, it does not prevent the rapid substitution rate and morbidity of the Omicron VOC.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: South America / Brazil Language: English Year: 2022 Document Type: Article Affiliation country: V14102148

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: South America / Brazil Language: English Year: 2022 Document Type: Article Affiliation country: V14102148